Life Healthcare Sees Earnings Rising 6%-11% in FY2026

The hospital group forecasts normalised earnings per share growth for the year to end-September 2026, while headline EPS is expected to fall.

Updated on Nov. 13, 2026 in Healthcare

Life Healthcare Sees Earnings Rising 6%-11% in FY2026

Life Healthcare expects normalised earnings per share from continuing operations to rise 6%-11% for the year to 30 September 2026, to between 106.3c and 111.3c. Headline earnings per share from continuing operations are expected to fall 1%-6%, to between 100.7c and 106c.

Why it matters

The gap between the two forecasts is largely explained by the R2.4bn net gain from the disposal of Life Molecular Imaging recorded in the 2025 financial year, which inflates the prior-year comparison. Investors and patients in South Africa and Botswana will watch whether hospital volumes recover after pressure from a medical scheme funder placed under curatorship.

Interim normalised EPS rose 8.4% to 53.1c and normalised EBITDA rose 5.2% to R2bn for the six months to end-March 2026. Paid patient days in the acute hospital business fell 0.9% like-for-like in the first half, so the guided growth depends on the second half.

The players

Life Healthcare

Life Healthcare is a South African private hospital group operating acute hospitals in South Africa and Botswana.

The details

The 2025 financial year included a R2.4bn net gain from the disposal of Life Molecular Imaging, and the pro forma figure adds back a R2.9bn fair-value adjustment on a liability linked to that business. Hospital operations faced pressure in the first half partly because a medical scheme funder was placed under curatorship, although occupancy improved in the second quarter to exceed 70%.

Timeline

  1. 2025 financial year: R2.4bn net gain from the Life Molecular Imaging disposal recorded.

  2. First half of the 2026 financial year: hospital pressure from the funder placed under curatorship.

  3. Six months to 31 March 2026: interim revenue of R12.4bn and normalised EPS of 53.1c reported.

  4. Second quarter of 2026: hospital occupancy improved to exceed 70%.

  5. 26 November 2026: expected release of full-year results.

Market Landscape

The guidance rests on normalising away the R2.4bn Life Molecular Imaging disposal gain, so the apparent growth is measured against a cleaner base than reported earnings. That makes the difference between the normalised and headline forecasts the central figure for comparing the group's performance with its own prior year.

Patients and medical scheme members in South Africa and Botswana are most directly affected by whether hospital volumes recover, since that drives the group's capacity and pricing. The forecast does not set out any change to patient fees or service levels.

The takeaway

Headline earnings and normalised earnings are moving in different directions this year, so readers should compare like with like before judging the group's performance. The full-year results on 26 November 2026 will show whether the second-half occupancy gains held.

What happens next

Life Healthcare is expected to release full-year results on or about 26 November 2026, when the guidance will be tested against actual performance.

Further reading

For more on the sector, see Healthcare coverage of private hospital groups in South Africa.